Trial reportTranslational vision science & technology2026
Microperimetry Sensitivity Changes at the Functional Transition Zone and at the EZ Margins in X-Linked Retinitis Pigmentosa Treated With Gene Therapy.
Trial report in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the structure-function relationship between the photoreceptor ellipsoid zone (EZ) and functional transition zone (FTZ) in X-linked retinitis pigmentosa (XLRP) eyes treated with gene therapy. Methods: In a post-hoc analysis of the Skyline trial, baseline OCT volumes were segmented to generate an en-face map of intact EZ, and after registration with microperimetry (MP) image, the transformed EZ map was used to delineate the EZ margin. FTZ was defined by microperimetry absolute scotomatous points. Non-scotomatous loci adjacent to FTZ, and inside the EZ margin, were analyzed. We quantified the percentage of loci with ≥7 dB sensitivity improvements over 12 months and the average treatment effect (ATE; difference in mean sensitivity change between treated and untreated eyes). Results: Twenty-four eyes (12 treated, 12 untreated; seven high-dose, five low-dose) were analyzed. Baseline distance to the EZ margin did not correlate with loci achieving ≥7 dB improvement at month 12 in either dose group. High-dose eyes showed a higher mean percentage of loci with ≥7 dB improvement than untreated eyes for the entire grid, but not on regional analysis. High-dose subjects also showed higher ATE than untreated eyes in all retinal zones. Conclusions: High-dose AAV-RPGR gene therapy was associated with improved MP outcomes and greater ATE inside FTZ and intact EZ; however, loci with ≥7 dB improvement did not correlate with baseline EZ margin distance, highlighting challenges in prespecifying localized ≥7 dB changes. Translational Relevance: Identifying and selecting retinal regions that are likely to show sensitivity improvements may benefit future clinical trials of ocular gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.